First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice

被引：0
|
作者：
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
ONCOLOGY-NEW YORK | 2013年 / 27卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [21] Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
    Ward, Kristen
    Citrome, Leslie
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 399 - 409
  • [22] Second-line ponatinib in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: An interim analysis of the PONS trial
    le Coutre, P.
    Burchert, A.
    Saussele, S.
    Pelzer, U.
    Bullinger, L.
    Elmaagacli, A.
    Jehn, C.
    Stegelmann, F.
    Hochhaus, A.
    Ernst, T.
    Goethert, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 69 - 69
  • [23] Therapy goals for first-line treatment in CML and implications for the doctor
    Saussele, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 1 - 1
  • [24] Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?
    Apostolidis, Apostolos
    CURRENT DRUG TARGETS, 2015, 16 (11) : 1187 - 1197
  • [25] Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Konopleva, Marina
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 477 - 484
  • [26] The choice of first-line Chronic Myelogenous Leukemia treatment
    Fava, Carmen
    Rege-Cambrin, Giovanna
    Saglio, Giuseppe
    ANNALS OF HEMATOLOGY, 2015, 94 : S123 - S131
  • [27] The choice of first-line Chronic Myelogenous Leukemia treatment
    Carmen Fava
    Giovanna Rege-Cambrin
    Giuseppe Saglio
    Annals of Hematology, 2015, 94 : 123 - 131
  • [28] Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial
    le Coutre, Philipp
    Goethert, Joachim R.
    Saussele, Susanne
    Pelzer, Uwe
    Bullinger, Lars
    Elmaagacli, Ahmet
    Jehn, Christian
    Stegelmann, Frank
    Hochhaus, Andreas
    Ernst, Thomas
    Burchert, Andreas
    BLOOD, 2022, 140 : 12202 - 12203
  • [29] A COMPARISON OF METHODOLOGIES FOR ESTIMATING SURVIVAL IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE-KINASE INHIBITORS (TKIS) FOR CHRONIC MYELOID LEUKAEMIA (CML)
    Pennington, B.
    Batty, A. J.
    Clifton-Brown, E.
    VALUE IN HEALTH, 2013, 16 (07) : A326 - A327
  • [30] Therapeutic Results of Second-Generation TKIs in a CML Multicentric Study in the West Region of Algeria
    Nadjat, Siali
    Mohamed, Benlazar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S292 - S292
12345